ACTRN12612000418875尚未招募不适用
A multi-centre randomised, placebo controlled trial of nebulised heparin in patients with or at risk of developing Acute Respiratory Distress Syndrome, to determine if nebulised heparin improves long term physical function.
St.Vincents Hospital/Institute0 个研究点目标入组 256 人开始时间: 2012年4月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Receiving ventilation via an endotracheal tube
- •Started ventilation via an endotracheal tube yesterday or today
- •Expected to require invasive ventilation for at least all of today and all of tomorrow
- •PaO2 to FiO2 ratio less than 300
- •Active ventilator circuit humidification
排除标准
- •Allergy to heparin; any history of heparin induced thrombocytopenia
- •Platelet count less than 50 x 109/L; activated partial thromboplastin time (APTT) is prolonged to greater than 80 seconds and this is not due to anticoagulant therapy
- •Uncontrolled bleeding; pulmonary bleeding during this hospital admission; any history of intracranial, spinal or epidural haemorrhage
- •Neurosurgical procedures during this hospital admission or such procedures are planned; an epidural catheter is in place
- •Hepatic encephalopathy or any history of gastrointestinal bleeding due to portal hypertension or biopsy proven cirrhosis with documented portal hypertension
- •Tracheostomy in place; usually receives home oxygen; usually receives any type of assisted ventilation at home e.g. continuous positive airway pressure for obstructive sleep apnoea
- •Cervical spinal cord injury associated with reduced long-term ability to breathe independently; spinal or peripheral nerve disease with a likely prolonged reduction in the ability to breathe independently e.g. Guillain-Barre syndrome, motor neurone disease
- •Receiving high frequency oscillation ventilation or extra corporeal membrane oxygenation
- •Pregnant or might be pregnant
- •Treatment limits restrict the provision of renal replacement therapy, inotropes, vasopressors or prolonged invasive ventilation; usually treated with haemodialysis or peritoneal dialysis for end-stage renal failure; dementia; death is deemed imminent or inevitable or there is underlying disease with a life expectancy of less than 90 days
研究者
相似试验
进行中（未招募）
1 期
A multicentre, randomised, placebo controlled trial of lactic acid bacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 years and over admitted to hospital and receiving antibiotics (06/39/02)AAD is diarrhoea occurring in association with antibiotic treatment without an alternative cause. It occurs typically 2-8 weeks after exposure to antibiotics. The frequency of AAD varies markedly between studies according to risk factors such as exposure to broad-spectrum antibiotics, nosocomial infections and host factors such as age, health status, gender.MedDRA version: 9.1 Level: PT Classification code 10064065 Term: Prophylaxis against diarrhoeaEUCTR2007-002876-32-GBniversity of Wales Swansea2,974
已完成
不适用
Probiotics in the prevention of antibiotic-associated and C. difficile diarrhoeaISRCTN70017204Swansea University (UK)2,974
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-DEniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 20.0Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-PTniversité catholique de Louvain (UCL)296
进行中（未招募）
1 期
A multi-centre placebo-controlled clinical trial, to show, if treatment with the drug tested (mirabegron, trade name of the finished medication: Betmiga®)????? prevents/delays myocardial remodeling (thickening of the myocardial wall) in patients at high risk of developing diastolic heart failure (heart failure with preserved ejection fraction/HFpEF) due to their underlying structural heart disease.??????Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).MedDRA version: 19.1Level: LLTClassification code 10019290Term: Heart insufficiencySystem Organ Class: 100000004849EUCTR2015-003146-75-BEniversité catholique de Louvain (UCL)296